BRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14
BRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14
Oct 13 (Reuters) - Trillium Therapeutics Inc TRIL.TO :
路透10月13日電-Trillium Treateutics Inc TRIL.TO：
* TRILLIUM THERAPEUTICS - ON OCT 12, 2021, PFIZER VOLUNTARILY WITHDREW ITS HART-SCOTT-RODINO ACT FILING, AND EXPECTS TO RE-FILE SUCH FORM ON OR ABOUT OCTOBER 14
*延齡治療公司-2021年10月12日，輝瑞公司自願撤回了其Hart-Scott-Rodino ACT申報文件，預計將在10月14日左右重新提交此類表格
* TRILLIUM THERAPEUTICS INC - CO, PFIZER ARE WORKING COOPERATIVELY WITH APPLICABLE REGULATORY AUTHORITIES IN THEIR REVIEW OF PROPOSED ARRANGEMENT
*延齡治療公司(Trillium Treateutics Inc-CO)、輝瑞(Pfizer)正在與適用的監管機構合作，審查擬議的安排
* TRILLIUM THERAPEUTICS INC - CO, PFIZER CONTINUE TO EXPECT TO CONSUMMATE ARRANGEMENT IN Q4 OF 2021 OR FIRST HALF OF 2022
*延齡治療公司-CO，輝瑞公司繼續預計在2021年第四季度或2022年上半年完成安排
Further company coverage: TRIL.TO
進一步的公司報道：TRIL.TO